This inventor holds 10 USPTO granted patents and 16 published patent applications and 2 EPO patents. Top assignees: University of California, Children's Hospital Los Angeles, Leland Stanford Junior University. Active years: 1998-2026.
Location History:
- East Los Angeles, CA (US) (2020)
- Tarzana, CA (US) (1998 - 2024)
Company Filing History:
8 out of 15,977 
1 out of 69 
1 out of 5,492 
Years Active: 1998-2026
Title: The Innovative Contributions of Donald B Kohn
Introduction
Donald B Kohn is a prominent inventor based in Tarzana, California, known for his significant contributions to the field of gene therapy. With a total of five patents to his name, Kohn has made remarkable advancements in the development of lentiviral vectors for therapeutic applications.
Latest Patents
Among his latest patents is the "Self-inactivating lentiviral vector comprising a FOXP3 expression cassette." This invention provides lentiviral vectors that express FoxP3, utilizing endogenous gene elements to regulate the physiological gene expression of FoxP3. Another notable patent is the "Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies." This patent describes an optimized derivative of a lentiviral vector capable of driving lineage-restricted expression of a beta-globin gene, which is crucial for treating conditions like sickle cell disease.
Career Highlights
Kohn has had a distinguished career, working with esteemed institutions such as the University of California and Children's Hospital of Los Angeles. His work has focused on innovative solutions in gene therapy, particularly in the context of hematological disorders.
Collaborations
Throughout his career, Kohn has collaborated with notable professionals in the field, including Roger Paul Hollis and R Michael Blaese. These collaborations have further enhanced the impact of his research and inventions.
Conclusion
Donald B Kohn's contributions to gene therapy through his innovative patents and collaborations have significantly advanced the field. His work continues to inspire future research and development in therapeutic applications.